Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4
about
Alpha Klotho and phosphate homeostasisMICS, an easily ignored contributor to arterial calcification in CKD patients.Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients.Implications of Klotho in vascular health and disease.Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patientsFibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trialAssociation of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFRCorrelates and Longitudinal Renal and Cardiovascular Implications of FGF23 Levels in HIV-Positive Individuals.Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014Association between Serum Soluble Klotho Levels and Mortality in Chronic Hemodialysis Patients.External Validation of the Kidney Failure Risk Equation and Re-Calibration with Addition of Ultrasound ParametersResponse of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.The effect of nephrectomy on Klotho, FGF-23 and bone metabolism.The importance of klotho in phosphate metabolism and kidney disease.The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.Potential application of klotho in human chronic kidney disease.αKlotho and Chronic Kidney Disease.Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis.FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.Abnormalities in biomarkers of mineral and bone metabolism in kidney donors.Klotho Deficiency and the Cardiomyopathy of Advanced CKD.FGF23 and Left Ventricular Hypertrophy in Children with CKD.Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction.Tubular Cell Senescence in the Donated Kidney Predicts Allograft Function, but Not Donor Remnant Kidney Function, in Living Donor Kidney Transplantation.The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease.Pleiotropic Actions of FGF23.Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis.Phosphate and Cardiovascular Disease beyond Chronic Kidney Disease and Vascular Calcification.Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease.Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial StabilityCardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome
P2860
Q26825471-D07C4A86-5A94-46D2-BDA4-96496FD8F38EQ30249410-3943C044-942C-48FA-A1E6-D6D1186AA919Q34204949-764A9935-B3E0-4940-B386-2852D8A718DAQ34780123-0654021B-00A7-403C-B67C-26188E3AC468Q34941418-D4111DAE-44CF-42AE-AC8D-9E1E620ADED5Q35008805-E5E301C3-5FE8-40F5-8BD5-B9EF4EFA6AA5Q35082659-7D1A2E66-ADE5-4975-88EB-47D133F519D3Q35901123-13D96CF9-9F03-48FA-AD4C-2557F3149D69Q36016861-1882AC44-5365-42DD-B9EB-5471F39DF895Q36123640-34E4054C-1306-4BA7-BB38-9E9B540E2B5EQ36269865-FC7A6DB5-1FA6-464E-B70C-A2FA8516F4BCQ36770904-9C823234-6B86-41BF-A99A-96C9DC6A66FFQ37432867-A616875D-C9C1-456D-B0DA-E336400A8EBCQ37710161-252C6F07-A32C-4AE5-823A-7962180BDCC6Q38205938-72198A53-E0B7-4EAC-AF3A-D2A1B807EF21Q38584122-9586BC51-FAD3-459F-B363-48B3F05CD8B4Q39003568-C899838E-F8AB-43A3-9841-33ABED91E886Q39812781-0222B9AC-4CC2-4741-ACBE-07F19DEA4122Q40279706-FCAB9AC3-F3C7-414A-A003-3116B7D464C7Q40687018-28568CAA-34AD-42E3-9D57-F5672310AE73Q41652359-7E165FD7-79E4-4E3B-A3B6-CA0411A6AF5CQ42943144-2B5D9B28-CD04-4EBB-B92B-65A8FB21EB07Q46192114-716893BE-68EF-482C-9C15-E30E55D41D51Q46219047-0CEA0AB1-8867-4CB4-AB29-C835881E2931Q48541526-AC6ECA83-1431-43D7-93A2-568B08C2CBBEQ49593339-4BC76A11-1B88-4A2E-AFC8-F603E8319982Q51765638-7420EB9C-7364-4368-9C02-3566EE998A26Q52673330-722499A8-FA41-4DEC-9D0F-99D27EE58136Q54139850-A1383571-B63D-439C-8753-08AC2EC00941Q54982565-76CA44DC-5E6C-488F-AEDE-E18F5EBFC626Q55098165-D95A8454-F600-47BD-8518-FF1AB605F4EDQ55442487-9AFFC3B0-1F58-4C53-B7A0-2E7937B2E18BQ58127469-B3D7796B-5E9B-4E04-B6FD-BD723D00E745Q58773641-625C55A3-6EDE-4287-A26C-DFF202B19C4B
P2860
Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Associations of FGF-23 and sKl ...... g patients with CKD stages 2-4
@ast
Associations of FGF-23 and sKl ...... g patients with CKD stages 2-4
@en
type
label
Associations of FGF-23 and sKl ...... g patients with CKD stages 2-4
@ast
Associations of FGF-23 and sKl ...... g patients with CKD stages 2-4
@en
prefLabel
Associations of FGF-23 and sKl ...... g patients with CKD stages 2-4
@ast
Associations of FGF-23 and sKl ...... g patients with CKD stages 2-4
@en
P2093
P2860
P356
P1476
Associations of FGF-23 and sKl ...... g patients with CKD stages 2-4
@en
P2093
Danilo Fliser
Gunnar H Heine
Heinz J Roth
Insa Emrich
Jürgen Floege
Kyrill S Rogacev
Pagah Shafein
Sarah Seiler
Stefan Neuhaus
P2860
P304
P356
10.2215/CJN.07870713
P577
2014-03-27T00:00:00Z